Latest Regulatory Development News

Golden Cross Resources reported a quiet December quarter with ongoing preparatory work at its flagship Copper Hill copper-gold project, while its ASX securities remain suspended pending operational compliance.

Northern Minerals has made significant strides in developing its Browns Range Heavy Rare Earths Project, securing substantial funding support from US and Australian agencies alongside a $60.5 million capital raise. Exploration success and engineering progress position the company for a Final Investment Decision by late 2026.

ioneer Ltd has raised approximately US$50.4 million through an institutional placement to fund the advancement of its Rhyolite Ridge lithium-boron project in Nevada towards a Final Investment Decision in the second half of 2026. The capital injection supports project readiness, environmental permitting, and early works for this strategically significant US critical minerals asset.

AKORA Resources has completed a significant trenching program at its Bekisopa iron ore project in Madagascar and submitted a mining permit application under a revitalised regulatory framework, gaining strong government backing.

Evion Group gains momentum as the US-Africa Strategic Infrastructure and Investment Working Group fosters trade, Madagascar accelerates mining permits, and Indian graphite operations deliver strong sales.

LCL Resources reported promising high-grade gold-copper-silver assays from trenching in Papua New Guinea and is actively pursuing lower-risk jurisdiction assets while advancing its Colombian option agreement.

ASF Group Limited closed December 2025 with $1.91 million in cash and nearly four quarters of funding runway, while progressing key investments in mining, technology, and biotech sectors.

EMC Gold has withdrawn its Salave Gold Project’s strategic interest application to strengthen future submissions, while raising €2.64 million from Spanish investors to advance engineering work.

NGX Limited has progressed its natural graphite exploration in Malawi and uranium projects in Namibia, while maintaining a robust financial footing with $2.7 million cash and no debt. The company is actively pursuing strategic partnerships and development pathways aligned with the clean energy transition.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.